Quickly & safely dissolve thrombus with the EKOS™ System.

Treat smarter. Achieve more.™

Since its beginning, EKOS™ has had one goal: develop life-enhancing and lifesaving endovascular treatments for vascular thrombosis. EKOS™ is committed to developing device-based therapies that improve patient outcomes, lower risks and improve treatment predictability.

The Acoustic Pulse Difference

EKOS™ Acoustic Pulse Thrombolysis™ treatment is a minimally invasive system for dissolving thrombus. The ultrasonic core generates a localised acoustic field which greatly accelerates lytic dispersion by driving the drug deeper into the clot and unwinding the fibrin to expose plasminogen receptor sites.

Acoustic Pulse Thrombolysis™ Treatment:

- Speeds time-to-dissolution
- Increases thrombus removal and clinical improvement compared to either standard Catheter Directed Therapy (CDT) or thrombectomy2,4
- Lowers the risk of bleeding and other complications2,4

More Effective Drug Delivery:

- Reduces dosage requirements by as much as 68% compared to standard CDT
- Requires up to 4x less drug dosage than systemic delivery6,7

Superior Thrombus Clearance2,4:

- 48% greater drug absorption within 1 hour8
- 84% greater drug absorption within 2 hours8

The EKOS™ System's targeted ultrasound waves accelerate thrombus dissolution by unwinding the fibrin matrix.

The fast, safe solution for vascular thrombosis.

The EkoSonic™ Endovascular System:

- Quality clinical outcomes
- Predictable results
- Minimised bleeding risk
- Efficient procedures

The Thrombosis Barrier

Tightly wound fibrin prevents lytic from reaching receptor sites.

With Acoustic Pulse

Ultrasound energy thins fibrin and exposes receptor sites.

With Acoustic Pulse + Lytic

More drug reaches entire thrombus, accelerating absorption.

Deep Vein Thrombosis

- 50% of DVT patients have PE
- Removes thrombus more completely compared to CDT10
- Reduces post-thrombotic syndrome11

Arterial Occlusion

- Lower 30-day amputation rate2
- Lower bleeding rates when compared to CDT
- Higher complete dissolution rate of thrombus2

Pulmonary Embolism

- Reduces RV/LV ratio by more than 25% on average8
- Reduces PA pressures by 28% (at 48 hours)7
- 76% less thrombolytic drug dosage than standard treatment7
- Minimised risk of bleeding6

The EKOS™ effect (in green) changes the standard of care for pulmonary embolism and dissolves the thrombus more completely, even in difficult-to-reach areas for deep vein thrombosis and peripheral arterial occlusion.
The fast, safe solution for vascular thrombosis.

The EkoSonic™ Endovascular System:
- Quality clinical outcomes
- Predictable results
- Minimised bleeding risk
- Efficient procedures

Lower patient risk. Higher procedure predictability.

Targeting the Thrombus, Safely Reduced Procedure Time

The EkoSonic™ Endovascular System includes an ultrasonic core within an infusion catheter, and control unit.

With EKOS® Acoustic Pulse Thrombolysis™ treatment most of the drug remains in the thrombus and you can typically use less lytic. It dissolves the thrombus without damaging vessels, valves or walls. There is no mechanical disruption resulting in distal embolisation.

The EKOS™ System’s safety and efficacy is supported by Level 1 and Level 2 data.

EKOS® requires significantly shorter treatment times, typically only 33–50% of standard CDT. Unlike more complex surgical solutions, EKOS® is an efficient, three-step process:

1) Insert the EKOS® 5.4 F infusion catheter through the thrombus.
2) Insert the ultrasonic core until it locks in place.
3) Activate the lytic infusion and acoustic pulse.

Treatment zones range from 6cm to 50cm with radiopaque marker bands at each end of the treatment zone to enhance visualisation. At-a-glance operating status, alarms and treatment times are easy to read from a distance.
INDICATIONS FOR USE: The EkoSonic™ Endovascular System is intended for controlled and selective infusion of physician-specified fluids, including thrombolics, into the peripheral vasculature. The EkoSonic™ Endovascular System is CE Marked for the treatment of pulmonary embolism with a ≥50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥25 mmHg) or echocardiographic evaluation. Contraindications: Not designed for peripheral vasculature dilation purposes. This system is contraindicated when, in the medical judgment of the physician, such a procedure may compromise that patient’s condition. Such conditions include but are not limited to: • Tortuous vascular anatomy • Conditions associated with increased risk of bleeding. See device instructions for use for complete prescribing information http://ekoscorp.com/learningcenter.htm#Resources

The EkoSonic™ Endovascular System

About BTG

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to address some of today’s most complex healthcare challenges.

To learn more about BTG, please visit: www.btgplc.com.

All EKOS® products are latex free.

Contact us:

Address: Lakeview, Riverside Way, Watchmoor Park, Camberley, Surrey GU15 3YL UK

Email: customerservice@ekoscorp.com

Website: www.ekoscorp.com

Online Learning Center: www.ekoscorp.com/learningcenter.htm